logo-loader

Arix Bioscience portfolio company LogicBio announces IND clearance for LB-001

Published: 15:47 10 Aug 2020 BST

Arix Bioscience PLC -

Arix Bioscience PLC (LON:ARIX) has noted portfolio company LogicBio Therapeutics’ (Nasdaq:LOGC) approval for a Phase 1/2 clinical trial of its LB-001 programme for very young children with methylmalonic acidemia (MMA) .

LogicBio said it expects patient enrolment to begin in early 2021.

“We’re pleased to announce our plans for developing LB-001 in pediatric patients with MMA,” said Fred Chereau, CEO of LogicBio.

“This is an important milestone for patients, their families, our company and for the genetic medicines space more broadly as we believe this is the first Investigational New Drug application (IND) clearance for an in vivo gene editing program harnessing homologous recombination,”

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

47 minutes ago